Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,695 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total transaction of $14,322.75. Following the transaction, the chief financial officer directly owned 249,301 shares in the company, valued at $2,106,593.45. The trade was a 0.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total value of $105,308.40.

Relay Therapeutics Price Performance

Shares of Relay Therapeutics stock opened at $7.71 on Friday. The company has a market capitalization of $1.34 billion, a P/E ratio of -4.41 and a beta of 1.55. The business has a 50-day moving average of $7.96 and a two-hundred day moving average of $5.95. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, equities analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RLAY. Mirae Asset Global Investments Co. Ltd. grew its stake in Relay Therapeutics by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock valued at $71,000 after purchasing an additional 1,757 shares in the last quarter. Cresset Asset Management LLC grew its stake in shares of Relay Therapeutics by 5.0% in the third quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock valued at $203,000 after buying an additional 1,848 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in Relay Therapeutics by 8.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock worth $145,000 after buying an additional 2,079 shares during the last quarter. Prelude Capital Management LLC raised its position in Relay Therapeutics by 18.7% during the third quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock worth $103,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in Relay Therapeutics by 5.0% in the second quarter. Los Angeles Capital Management LLC now owns 68,615 shares of the company’s stock valued at $237,000 after acquiring an additional 3,275 shares during the last quarter. 96.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on RLAY shares. Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target on the stock in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Finally, Wells Fargo & Company upgraded Relay Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $13.00 in a research note on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.57.

Relay Therapeutics News Roundup

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Shares are trading up intraday, sitting above the 200?day moving average—a technical signal some investors view as constructive. MarketBeat RLAY quote
• Neutral Sentiment: Despite the recent sales, insiders still hold large positions (many hundreds of thousands of shares), which reduces the likelihood of a meaningful shift in strategic control; the disclosures show percentage ownership declines but substantial remaining stakes. (See SEC filings linked below.)
• Negative Sentiment: CFO Thomas Catinazzo sold 1,695 shares at an average $8.45 on Jan. 28 (total ~$14.3k), and had also sold 13,820 shares at ~$7.62 on Jan. 27; these filings show a multi-day reduction in the CFO’s ownership. Catinazzo filings
• Negative Sentiment: Insider Peter Rahmer sold 1,354 shares at $8.45 (Jan. 28) and 11,684 shares at $7.62 (Jan. 27), reducing his stake by several percent—more insider selling that can weigh on sentiment. Rahmer filings
• Negative Sentiment: Insider Donald A. Bergstrom sold 2,686 shares at $8.45 and 18,895 shares at $7.62 across Jan. 27–28, cutting his position by ~4%. Large, clustered insider sales can amplify near?term downward pressure. Bergstrom filings
• Negative Sentiment: Market commentary highlights recent weakness in RLAY (example: a note explaining a ~5.2% drop), which may reflect short?term sentiment, sector dynamics, or news-driven selling; that coverage can push momentum lower even if fundamentals are unchanged. Why RLAY is down 5.18%

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.